BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States Patent Office issued BioCardia Patent […]
Exploring the Benefits of MSCT for IHD
Introduction Mesenchymal Stem Cell Therapy (MSCT) is a promising, yet still experimental form of treatment that has the potential to revolutionize the management of Ischemic Heart Disease (IHD). What are Mesenchymal Stem Cells Mesenchymal stem cells (MSCs) are a type of adult stem cell found in the body that can differentiate into several different types […]